6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols

Quick Answer: Inhaled nicotine binds stereoselectively to $\alpha_4\beta_2$ nicotinic acetylcholine receptors (nAChRs) on dopaminergic neurons in the ventral tegmental area (VTA), eliciting rapid burst firing and massive dopamine efflux in the nucleus accumbens (NAc). Rapid receptor desensitization leads to a 300–400% compensatory upregulation of nAChR density, creating severe withdrawal symptoms (irritability, anxiety, restlessness, hedonic crash) within 60–120 minutes. Assessment relies on the Fagerström Test for Nicotine Dependence (FTND), where time to first cigarette after waking ($\le 5$ minutes = high dependence) is the single strongest predictor of physical dependence. First-line pharmacotherapies include Combination / Dual NRT (transdermal patch 21 mg/day for baseline kinetics plus rapid-acting 4 mg gum or lozenge for breakthrough cravings), Varenicline (0.5 mg daily $\to$ 0.5 mg BID $\to$ 1 mg BID; α4β2 partial agonist; proven neuropsychiatrically safe in the EAGLES trial), and Bupropion SR (150 mg daily $\to$ 150 mg BID; DNRI and nAChR antagonist). Bupropion is strictly contraindicated in patients with a history of seizures, anorexia or bulimia, abrupt alcohol/sedative withdrawal, or concurrent MAO inhibitor use.

---

1. Neurobiology of Nicotine Dependence & Receptor Kinetics

Tobacco Use Disorder (TUD) is among the most lethal and intractable substance use disorders encountered in clinical practice. The speed of delivery and complex allosteric receptor dynamics make nicotine uniquely habit-forming.

Inhaled Nicotine (Puffs reach brain in 7–10 seconds)
               │
               ▼
Binds Presynaptic α4β2 nAChR Pentamers in VTA
               │
               ▼
Influx of Ca²⁺ & Na⁺ ──▶ Depolarization & Burst Firing
               │
               ▼
Dopamine Efflux into Nucleus Accumbens Shell (Reward & Salience)
               │
               ▼
Rapid Receptor Desensitization (Channels lock in closed state)
               │
               ▼
Receptor Resensitization (Arterial nicotine drops, t½ ~2 hours)
               │
               ▼
Compensatory Upregulation (300–400% receptor density increase)
               │
               ▼
Cholinergic Hypofunction & Locus Coeruleus Hyperarousal ──▶ Craving & Withdrawal

Molecular Receptor Kinetics: The $\alpha_4\beta_2$ Pentamer

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels composed of combinations of $\alpha$ ($\alpha_2$ to $\alpha_{10}$) and $\beta$ ($\beta_2$ to $\beta_4$) subunits. The $\alpha_4\beta_2$ heteropentamer represents the primary mediator of nicotine dependence in the central nervous system:

• High-Affinity Agonism: Inhaled nicotine diffuses across alveolar capillaries into pulmonary venous circulation, entering cerebral circulation within 7 to 10 seconds—faster than intravenous administration. Nicotine binds with nanomolar affinity to the interfacial orthosteric binding pockets of $\alpha_4\beta_2$ nAChRs located on cell bodies and presynaptic terminals of dopaminergic projection neurons within the ventral tegmental area (VTA).
• Burst Firing & Dopamine Efflux: Agonist binding produces conformational rotation of M2 transmembrane helices, opening a central cation-selective pore. The resulting rapid inward influx of calcium ($Ca^{2+}$) and sodium ($Na^+$) depolarizes the membrane, switching dopaminergic neurons from tonic low-frequency pacemaking to high-frequency phasic burst firing. This generates massive dopamine efflux into the shell of the nucleus accumbens (NAc) and prefrontal cortex, reinforcing smoking behavior and encoding incentive salience.
• Receptor Desensitization: Within seconds to minutes of continuous agonist exposure, $\alpha_4\beta_2$ receptors transition into an inactive, non-conducting desensitized state. In this state, the channel pore remains closed despite bound ligand, rendering the neuron temporarily unresponsive to additional nicotine.
• Compensatory Receptor Upregulation: The chronic cycle of repeated agonist binding followed by prolonged receptor desensitization paradoxically causes homeostatic upregulation of nAChR density by 300% to 400% across the human cerebral cortex and mesolimbic circuitry. The brain synthesizes and traffics an abnormally vast excess of $\alpha_4\beta_2$ receptors to neuronal membranes to compensate for chronic desensitization.
• Resensitization & The Withdrawal-Craving Cycle: As circulating arterial nicotine concentrations decline (elimination half-life of nicotine is approximately 2 hours), the abundant upregulated receptors resensitize and revert to an unliganded resting state. Deprived of nicotine's stimulation, basal mesolimbic dopamine drops below baseline (reward deficit state), while excessive unliganded cholinergic receptors trigger widespread cholinergic hypofunction and disinhibit locus coeruleus noradrenergic hyperactivation. Within 60 to 120 minutes of the last cigarette, the patient experiences intense drug cravings, irritability, anxiety, autonomic tension, and difficulty concentrating.

---

2. Clinical Assessment & The Fagerström Test for Nicotine Dependence (FTND)

Accurate assessment of physical dependence guides the selection and intensity of pharmacotherapy. While DSM-5-TR establishes the diagnostic threshold for Tobacco Use Disorder (meeting $\ge 2$ of 11 behavioral and physiological criteria over 12 months), the Fagerström Test for Nicotine Dependence (FTND) is the gold-standard instrument for quantifying physical dependence severity.

The Fagerström Test for Nicotine Dependence (FTND)

[!IMPORTANT] Clinical Interpretation & Stratification:

• Total Score 0–2: Very low dependence
• Total Score 3–4: Low dependence
• Total Score 5: Medium dependence
• Total Score 6–7: High dependence
• Total Score 8–10: Very high dependence

The Pathognomonic First Morning Cigarette: Item 1 (Time to first cigarette after waking) is the single most predictive question on the instrument. A patient who reaches for a cigarette within $\le 5$ minutes of waking has severe nocturnal nicotine clearance and overwhelming receptor resensitization, identifying profound physical dependence and an elevated risk of early relapse. These individuals require aggressive, high-dose combination pharmacotherapy.

Objective Laboratory Biomarkers

1. Exhaled Carbon Monoxide (CO): Carbon monoxide binds to hemoglobin with an affinity 200–250 times greater than oxygen, producing carboxyhemoglobin ($COHb$). Exhaled CO measured via handheld electrochemical breath analysis reflects combustible tobacco exposure within the prior 4 to 6 hours (half-life of exhaled CO is 2–8 hours, prolonged during sleep). A cutoff of $>6\text{ to }8\text{ parts per million (ppm)}$ distinguishes active smokers from non-smokers.
2. Cotinine: Cotinine is the primary proximate proximate metabolite of nicotine, generated via hepatic CYP2A6 oxidation. Cotinine has an elimination half-life of 16 to 20 hours (compared to nicotine's 2 hours), making it an exceptionally reliable biomarker for validating abstinence over the prior 2 to 4 days:
   • Serum / Saliva: Non-smokers $<1\text{–}10\text{ ng/mL}$; active combustible smokers typically $>100\text{–}500\text{ ng/mL}$.
   • Urine: Quantitative cutoff $\ge 50\text{–}200\text{ ng/mL}$ confirms active tobacco or nicotine use. Cotinine does not distinguish combustible tobacco from NRT or electronic nicotine delivery systems (ENDS).

---

3. First-Line Pharmacotherapies: Dual/Combination NRT Prescribing Protocols

Clinical guidelines from the American Thoracic Society (ATS) and the US Public Health Service (USPHS) establish that Combination / Dual NRT is dramatically superior to monotherapy (odds ratio ~1.35 to 1.55 versus patch monotherapy; OR ~2.0 versus placebo). Monotherapy frequently fails because a single modality cannot replicate the dual kinetics of combustible cigarettes: a continuous baseline plateau plus rapid spikes in response to environmental triggers.

[Combination / Dual NRT Regimen]
 ├── 1. Long-Acting Transdermal Patch ──▶ Sustained, zero-order baseline plasma levels
 │                                         (Prevents baseline withdrawal and physical cravings)
 └── 2. Short-Acting Breakthrough Agent ──▶ Rapid buccal/nasal spikes on-demand
     (Gum, Lozenge, Inhaler, Spray)        (Suppresses acute cue-induced craving surges)

Transdermal Nicotine Patch: Baseline Kinetics & Dosing

The transdermal patch delivers nicotine across the stratum corneum via slow zero-order diffusion, achieving steady plasma concentrations over 24 hours. Peak plasma levels are reached 4 to 9 hours post-application.

• Heavy Smokers ($>10$ cigarettes/day [half-pack or more], or FTND $\ge 6$):
  • Step 1: $21\text{ mg/24 hours}$ daily for 4 to 6 weeks
  • Step 2: $14\text{ mg/24 hours}$ daily for 2 weeks
  • Step 3: $7\text{ mg/24 hours}$ daily for 2 weeks
• Light Smokers ($\le 10$ cigarettes/day, or body weight $<45\text{ kg}$):
  • Step 2: $14\text{ mg/24 hours}$ daily for 6 weeks
  • Step 3: $7\text{ mg/24 hours}$ daily for 2 weeks
• Application Instructions & APRN Counseling:
  • Apply once daily every morning to clean, dry, hairless skin of the upper outer arm, chest, or upper back. Rotate anatomical sites daily to avoid contact dermatitis.
  • Sleep Disturbances & Vivid Dreams: If the patient experiences nocturnal insomnia or vivid/nightmarish dreams, the patch may be removed at bedtime (creating a 16-hour wear schedule), though morning withdrawal upon waking will be higher.

Short-Acting Breakthrough Formulations

Short-acting NRT formulations are titrated on-demand to neutralize breakthrough cravings triggered by classical conditioning (e.g., driving, post-meal, social cues):

1. Nicotine Polacrilex Gum: Available in $2\text{ mg}$ and $4\text{ mg}$ formulations.
   • Dosing Rule: If the patient smokes their first cigarette $\le 30$ minutes of waking, use the $4\text{ mg}$ strength; if $>30$ minutes, use the $2\text{ mg}$ strength. Minimum 9 pieces/day for first 6 weeks (maximum 24 pieces/day).
   • Administration Technique ("Chew and Park"): Chew slowly until a peppery taste or tingling sensation emerges (~15 chews); immediately "park" the gum between the buccal mucosa and gum tissue to allow passive transmucosal absorption. When tingling subsides, chew again and re-park on the opposite side. Discard after 30 minutes. Common Error: Chewing continuously like confectionary gum causes swallowing of nicotine, producing severe dyspepsia, hiccups, nausea, and blunted systemic absorption.
   • Acidic Beverage Restriction: Patients must avoid acidic beverages (coffee, tea, soda, citrus juices, wine) for 15 minutes before and during gum or lozenge use. Acidic pH protonates nicotine, creating an ionized form that cannot cross the lipophilic buccal epithelium.
2. Nicotine Lozenge: Available in $2\text{ mg}$ and $4\text{ mg}$ strengths (utilizing the same 30-minute waking rule). Allowed to dissolve slowly in the mouth over 20 to 30 minutes without chewing or swallowing. Delivers ~25% more nicotine than equivalent gum doses.
3. Nicotine Nasal Spray: $10\text{ mg/mL}$ solution delivering $0.5\text{ mg}$ per spray ($1\text{ spray}$ in each nostril $= 1\text{ mg}$ dose). Offers the fastest pharmacokinetic absorption of any NRT (peak plasma levels achieved in 5–10 minutes), closely mimicking the rapid onset of a cigarette. Initial dosage is 1–2 doses/hour (minimum 8 doses/day, max 40 doses/day). Frequent initial adverse effects include severe nasal burning, sneezing, and lacrimation (tachyphylaxis occurs within 48–72 hours). Relative contraindication in severe reactive airway disease or chronic nasal pathology.
4. Nicotine Oral Inhaler: Consists of a mouthpiece and plastic cartridge delivering $4\text{ mg}$ of vapor ($2\text{ mg}$ absorbed across the buccal mucosa, not pulmonary alveoli). Uniquely addresses the behavioral and sensory hand-to-mouth ritual of smoking. Best used with frequent shallow puffing (80 deep puffs per cartridge over 20 minutes; 6–16 cartridges/day).

Overview of First-Line NRT Prescribing Protocols

---

4. Varenicline (Chantix): Pharmacology, Titration & The EAGLES Trial

Varenicline tartrate is a synthetic small molecule derived from the plant alkaloid cytisine, representing the most effective single-agent pharmacotherapy for tobacco cessation.

Mechanism of Action

Varenicline is a selective, high-affinity partial agonist at $\alpha_4\beta_2$ neuronal nicotinic acetylcholine receptors:

• Agonist Properties (Low-Level Intrinsic Efficacy): Varenicline exhibits approximately 40% to 60% of the maximal dopamine-releasing capacity of full agonist nicotine. By sustaining modest, basal dopaminergic tone in the nucleus accumbens, varenicline substantially alleviates the dysphoria, craving, and autonomic distress of acute nicotine withdrawal.
• Antagonist Properties (Competitive Blunting): Because varenicline binds to the $\alpha_4\beta_2$ receptor with significantly higher affinity than nicotine itself, it competitively occupies and blocks the binding site. If a patient slips and smokes a combustible cigarette while taking varenicline, nicotine is prevented from binding to the receptor. The patient experiences no dopaminergic surge or hedonic reinforcement, extinguishing the conditioned reward response.

[Varenicline at α4β2 nAChRs]
       │
       ├─▶ Partial Agonism (40–60% baseline dopamine) ──▶ Alleviates Withdrawal & Cravings
       │
       └─▶ Competitive Blockade (Prevents Nicotine Binding) ──▶ Blunts Hedonic Reward upon Lapse

Clinical Prescribing & Titration Protocol

To minimize adverse gastrointestinal effects, varenicline must be incrementally titrated over one week before reaching the therapeutic target dose:

• Days 1 to 3: $0.5\text{ mg}$ PO once daily in the morning
• Days 4 to 7: $0.5\text{ mg}$ PO twice daily (morning and evening)
• Day 8 through Week 12 (Target Quit Date Window): $1.0\text{ mg}$ PO twice daily
• Target Quit Date Timing: The patient is advised to set a target quit date between Day 8 and Day 14 (1 to 2 weeks after initiating therapy), allowing the drug to reach steady-state plasma concentrations. Alternatively, a flexible quit approach allows quitting between days 8 and 35, or a gradual reduction approach over 12 weeks.
• Duration of Therapy: Standard duration is 12 weeks. In patients who successfully achieve complete abstinence at 12 weeks, an additional 12 weeks of maintenance therapy (total 24 weeks) is strongly recommended to consolidate abstinence and prevent delayed relapse.
• Renal Impairment Dosing: Varenicline undergoes minimal hepatic metabolism and is primarily eliminated unchanged by the kidneys ($>90%$). For patients with severe renal impairment (Creatinine Clearance $<30\text{ mL/min}$), the initial dose is $0.5\text{ mg}$ once daily, titrated to a maximum of $0.5\text{ mg}$ twice daily.

Adverse Effects & Mitigation Strategies

• Nausea: Occurs in up to 30% of patients. It is dose-dependent and typically transient. Mitigation: Counsel patients to ingest varenicline with a full meal and a large glass of water (8 oz). If persistent, down-titrate to $0.5\text{ mg}$ BID.
• Neuropsychiatric / Sleep Disturbances: Vivid, abnormal, or bizarre dreams and insomnia occur in 10–15% of patients. Mitigation: Shift the second daily dose from bedtime to dinner time (early evening, 5–6 PM) to reduce nocturnal peak cerebral drug concentrations.

The Landmark EAGLES Trial

Historically, post-marketing reports prompted the FDA to place a black box warning on varenicline and bupropion in 2009 regarding potential risks of severe neuropsychiatric symptoms (suicidality, depression, psychosis). To definitively assess this risk, the FDA mandated the EAGLES Trial (Evaluating Adverse Events in a Global Smoking Cessation Study, published in The Lancet, 2016):

• Design: A rigorous, double-blind, randomized, triple-dummy, active- and placebo-controlled trial across 16 countries, enrolling 8,144 adult smokers stratified into two distinct cohorts: a psychiatric cohort ($n=4,116$, with stable major depression, bipolar disorder, anxiety disorders, or schizophrenia) and a non-psychiatric cohort ($n=4,028$). Participants received varenicline 1 mg BID, bupropion SR 150 mg BID, nicotine transdermal patch 21 mg/d, or placebo for 12 weeks.
• Safety Findings: In both the psychiatric and non-psychiatric cohorts, there was no significant increase in serious neuropsychiatric adverse events (clinically significant suicidal ideation/behavior, aggression, psychosis, or panic) with varenicline or bupropion compared to nicotine patch or placebo.
• Efficacy Findings: Varenicline demonstrated superior continuous abstinence rates compared to bupropion (odds ratio ~1.4), nicotine patch (OR ~1.3), and placebo (OR ~3.6) at weeks 9–12 and weeks 9–24.
• Regulatory Outcome: Based on the conclusive EAGLES data, the FDA officially removed the black box warning from varenicline and bupropion in December 2016, establishing varenicline as a safe, first-line agent in patients with co-occurring psychiatric disorders.

---

5. Bupropion SR (Zyban): Mechanism, Dosing & Mandatory Contraindications

Bupropion sustained-release (SR) is an effective non-nicotine oral pharmacotherapy initially formulated as an antidepressant.

Neuropharmacology

• Dopamine and Norepinephrine Reuptake Inhibition (DNRI): Bupropion and its active hepatic metabolites (hydroxybupropion) inhibit the dopamine active transporter (DAT) and norepinephrine transporter (NET) in the prefrontal cortex and nucleus accumbens. By increasing synaptic dopamine concentrations, bupropion attenuates the profound anhedonia and dysphoria of acute nicotine withdrawal.
• Non-Competitive nAChR Antagonism: Bupropion acts as a functional, non-competitive antagonist at multiple nicotinic receptor subtypes, including $\alpha_4\beta_2$ and $\alpha_3\beta_4$. This antagonism blocks nicotine-mediated excitation.
• Weight Attenuation: Bupropion uniquely delays or blunts post-cessation weight gain during active therapy, making it especially appealing for patients with body image concerns.

Dosing Protocol

• Days 1 to 3: $150\text{ mg}$ PO once daily in the morning
• Day 4 through Week 7–12: $150\text{ mg}$ PO twice daily
• Spacing Requirement: Doses must be administered at least 8 hours apart to prevent high peak drug concentrations that reduce the seizure threshold. The second dose should be taken in the late afternoon (e.g., 4–5 PM) to minimize severe insomnia.
• Target Quit Date: Set for 1 to 2 weeks after starting bupropion, ensuring therapeutic steady-state concentrations prior to tobacco discontinuation.

Mandatory Clinical Contraindications

Bupropion reduces the electroencephalographic seizure threshold in a dose-dependent manner (seizure incidence is approximately 0.1% at doses $\le 300\text{ mg/day}$, escalating tenfold at $>450\text{ mg/day}$). The APRN must master the following absolute contraindications:

[MANDATORY CONTRAINDICATIONS FOR BUPROPION]
 ├── 1. Current or Prior Seizure Disorder (Epilepsy, febrile seizures)
 ├── 2. Current or Past Diagnosis of Anorexia Nervosa or Bulimia Nervosa
 ├── 3. Abrupt Discontinuation of Alcohol, Benzodiazepines, Barbiturates, or Antiepileptics
 ├── 4. Concurrent Administration of MAOIs (or within 14 days of stopping MAOI)
 └── 5. Severe Pre-existing Head Trauma or Active Central Nervous System Neoplasm

1. Current or Prior Seizure Disorder: Any personal history of unprovoked seizures or epilepsy absolutely precludes bupropion prescribing.
2. Current or Past Diagnosis of Bulimia Nervosa or Anorexia Nervosa: In pre-marketing trials, patients with active or historical purging behaviors experienced an unacceptably high rate of grand mal seizures (approximately 4%) due to transient electrolyte disturbances, fluid shifts, and metabolic dysregulation.
3. Abrupt Discontinuation of Alcohol, Sedatives, or Antiepileptics: Discontinuation of GABAergic modulators dramatically lowers the seizure threshold; concurrent bupropion creates a catastrophic seizure risk.
4. Concurrent Monoamine Oxidase Inhibitor (MAOI) Use: Administration within 14 days of an MAOI can precipitate a life-threatening hypertensive crisis.

---

6. Comparative Synthesis of First-Line Prescribing Options